Sir,
The antivascular endothelial growth factor aptamer pegaptanib may induce short-term regression of retinal neovascularisation secondary to diabetes.1 We present two diabetic patients who underwent intravitreal pegaptanib for persistent retinal neovascularisation and developed the progression of a previously stable tractional retinal detachment (TRD).
Case reports
Case 1
A 26-year-old woman with severe proliferative diabetic retinopathy underwent extensive scatter laser photocoagulation (PRP) leading to the regression of neovascularisation and a localised right inferotemporal TRD.
After 6 months, the TRD appeared unchanged, but fresh vitreous and preretinal haemorrhages were observed. Informed consent was obtained for intravitreal pegaptanib (0.3mg/0.9 ml).
Ten days after injection, the TRD appeared stable (Figure 1). By 5 weeks, TRD progression had resulted in macular elevation and reduced visual acuity from 6/12 to 6/36 (Figure 2).
The patient underwent vitrectomy, delamination, endolaser, and sulphur hexafluoride gas with minimal intraoperative haemorrhage. After 2 months, the visual acuity was 6/12.
Case 2
A 48-year-old woman with proliferative diabetic retinopathy underwent extensive PRP and developed TRD associated with regressed inferotemporal neovascularisation. After 8 months, active neovascularisation recurred although the TRD remained unchanged (Figure 3a and b).
Informed consent was obtained for intravitreal pegaptanib (0.3mg/0.9 ml). Three weeks later, although neovascularisation and preretinal haemorrhage had improved, the TRD had progressed and visual acuity reduced from 6/36 to counting fingers (Figure 4a and b).
The patient underwent right vitrectomy, delamination, and octafluoropropane gas. Minimal intraoperative haemorrhage permitted a low infusion pressure during surgery. After 6 weeks, the visual acuity was 6/12.
Comment
The preexisting TRD had remained stable for 6 months and 8 months in cases 1 and 2, respectively before progressing within the weeks of intravitreal pegaptanib. Reports exist of TRD progression following intravitreal bevacizumab in proliferative diabetic retinopathy.2, 3 However, there are currently no reports in the literature associating intravitreal pegaptanib with TRD progression.
Intravitreal pegaptanib did, however, result in less intraoperative haemorrhage than expected. This reduced the risk of further circulatory compromise in a diabetic due to prolonged elevated intraocular pressure while attempting to achieve haemostasis.
We feel that the rapid progression of the TRD in these patients is largely attributable to the pegaptanib. Although intravitreal pegaptanib may potentially be a useful management tool in severe proliferative diabetic retinopathy, in patients with preexisting TRD, we would advise caution and careful monitoring following its use.
References
Adamis AP, Altaweel M, Bressler NM, Cunningham Jr ET, Davis MD, Goldbaum M et al. Macugen Diabetic Retinopathy Study Group. Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology 2006; 113: 23–28.
Arevalo JF, Maia M, Flynn Jr H, Saravia M, Avery RL, Wu L et al. Tractional retinal detachment following intravitreal bevacizumab (Avastin(R)) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol 2008; 92: 213–216.
Tranos P, Gemenetzi M, Papandroudis A, Chrisafis C, Papadakos D . Progression of diabetic tractional retinal detachment following single injection of intravitreal Avastin. Eye 2007; (e-pub ahead of print).
Author information
Authors and Affiliations
Additional information
Radhika Krishnan would like to declare on behalf of the authors that they have no competing interests regarding this report and have not received any public or private support in relation to it.
Rights and permissions
About this article
Cite this article
Krishnan, R., Goverdhan, S. & Lochhead, J. Intravitreal pegaptanib in severe proliferative diabetic retinopathy leading to the progression of tractional retinal detachment. Eye 23, 1238–1239 (2009). https://doi.org/10.1038/eye.2008.179
Published:
Issue Date:
DOI: https://doi.org/10.1038/eye.2008.179
This article is cited by
-
A review of anti-VEGF agents for proliferative diabetic retinopathy
Eye (2014)
-
Intravitreal bevacizumab for proliferative diabetic retinopathy with new dense vitreous hemorrhage after full panretinal photocoagulation
Eye (2013)
-
Use of pegaptanib for recurrent and non-clearing vitreous haemorrhage in proliferative diabetic retinopathy
Eye (2010)